The prices of Carbamazepine IP Ex-Vadodara in Indian market have continued their downward trajectory in early September xxxx. The market sustained the declining trend which began in Qx xxxx. This was not a result of weak demand but rather a calculated market correction which was driven by government-backed initiatives and strategic supplier pricing. The downstream demand from pharmaceuticals, nutraceuticals and related healthcare sectors has adjusted to seasonal production cycles with Carbamazepine buyers managing their inventories cautiously after previous stockpiling. The Indian government鈥檚 Production Linked Incentive (PLI) scheme with increased supply of Carbamazepine from Asian producers has eased the earlier post-pandemic price inflation which prompted the buyers to recalibrate procurement strategies in anticipation of further softening.
The Carbamazepine market has been undergoing a structural shift since mid-xxxx. The prices of Carbamazepine which had been inflated as the aftermath of COVID-xx due to supply chain disruptions,...
